B7-H3-targeted natural killer cells are effective against atypical teratoid / rhabdoid tumors and extend survival in orthotopic xenografts
Neuro-Oncology · 13.11.2026
DOI: 10.1093/neuonc/noag285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 13.11.2026. Verfasst von Jun Choe und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore MD.
Abstract (Originalsprache)
Background
Atypical teratoid/rhabdoid tumors (ATRTs) are the most common malignant CNS tumor in infants, and patients suffer from low survival rates and treatment-related morbidities. These tumors frequently overexpress the pan-cancer antigen B7-H3 (CD276), which can be targeted with immunotherapy. We hypothesized that adding a B7-H3-targeting cytotoxic chimeric antigen receptor (CAR) to NK cells can enhance killing against ATRTs.
Methods
We designed a library of variable affinity B7-H3-targeted CARs, which were transduced into primary healthy donor-derived NK cells. We verified B7-H3 expression in a panel of ATRT cell lines and further engineered luciferase and nuclear GFP-expressing ATRT (CHLA-04, CHLA-06, BT12, BT37) as well as a CHLA-06-derived B7-H3 knockout. We tested CAR-NK cell functionality using in vitro co-culture cytotoxicity assays. We delivered anti-B7-H3 CAR-NK cells intratumorally or intracerebroventricularly (ICV) to ATRT orthotopic xenografts and monitored for tumor growth and animal survival.
Results
B7-H3-targeted CAR-NK cells demonstrated target-specific cytotoxicity when compared to unmodified NK cells. Knockout of B7-H3 in target cells abolished the increased CAR-mediated target killing. When delivered intratumorally to CHLA-06 orthotopic xenograft-bearing mice, anti-B7-H3 CAR-NK cells eliminated tumor cells and prolonged survival. When CAR-NK cells were delivered ICV against a CNS disseminated tumor model of BT12, treated mice had significantly improved survival.
Conclusions
Anti-B7-H3 CAR-NK cells effectively kill ATRTs in multiple pre-clinical in vitro and in vivo models in an antigen-specific manner. Evidence of efficacy in translationally relevant models provides support for using B7-H3-targeting CAR-NK cells in high-risk ATRT patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore MD.
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore MD.
Zitieren
APA
Choe, J., Chakravarti, S., Holl, N. J., Zinsky, M. T., Jones, D. G., Guchhait, S., Rahnama, R., Vorri, S. C., Geethadevi, A., Liu, S., Amaral, A., Lucas, C. G., Raabe, E. H., & Bonifant, C. L. (2026). B7-H3-targeted natural killer cells are effective against atypical teratoid / rhabdoid tumors and extend survival in orthotopic xenografts. Neuro-Oncology. https://doi.org/10.1093/neuonc/noag285
Vancouver
Choe J, Chakravarti S, Holl NJ, Zinsky MT, Jones DG, Guchhait S, et al. B7-H3-targeted natural killer cells are effective against atypical teratoid / rhabdoid tumors and extend survival in orthotopic xenografts. Neuro-Oncology. 2026. doi:10.1093/neuonc/noag285
BibTeX
@article{Choe2026,
author = {Choe, Jun and Chakravarti, Sachiv and Holl, Natalie J and Zinsky, Megan T and Jones, Danielle G and Guchhait, Shramana and Rahnama, Ruyan and Vorri, Stamatia C and Geethadevi, Anupa and Liu, Shiyu and Amaral, Adrianna and Lucas, Calixto-Hope G and Raabe, Eric H and Bonifant, Challice L},
title = {B7-H3-targeted natural killer cells are effective against atypical teratoid / rhabdoid tumors and extend survival in orthotopic xenografts},
journal = {Neuro-Oncology},
year = {2026},
doi = {10.1093/neuonc/noag285}
}
EUVIMED